Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the fourth quarter and year ended December 31, 2022.
Molina Healthcare will issue its earnings release for the fourth quarter and year ended December 31, 2022, after the market closes on Wednesday, February 8, 2023, and will host a conference call and webcast to discuss the earnings release on Thursday, February 9, 2023, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 3561497. A telephonic replay of the conference call will be available through Thursday, February 16, 2023, by dialing (877) 344-7529 and entering the confirmation number, 8594444.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.2 million members as of September 30, 2022. For more information about Molina Healthcare, please visit molinahealthcare.com.
Last Trade: | US$294.64 |
Daily Change: | 12.14 4.30 |
Daily Volume: | 584,711 |
Market Cap: | US$16.850B |
November 18, 2024 October 23, 2024 October 16, 2024 July 23, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB